While numerous cytogenetic abnormalities and mutations have been identified in AML, the receptor tyrosine kinase FMS-like tyrosine kinase 3 (Flt3) is mutated in approximately 30% of all AML cases [4,5]. This evidence concerns the gene FLT3 and acute myeloid leukemia.